ea0049oc6.2 | Diabetes therapy and complications | ECE2017
Ermetici Federica
, Briganti Silvia
, Benedini Stefano
, Codella Roberto
, Maffi Paola
, Caldara Rossana
, Secchi Antonio
, Piemonti Lorenzo
, Alejandro Rodolfo
, Ricordi Camillo
, Luzi Livio
It has been suggested that the selective m-TOR inhibitor, Rapamycin, has been improved the success pancreatic islet allotransplantation (ITx) in type 1 diabetic patients (T1DM). Forty-one ITx were studied. Thirteen T1DM in poor glycemic control underwent a 45-days Rapamycin before ITx followed by standard Edmonton Protocol (EP, group 1, Milan), and they were compared to 28 T1DM patients undergoing EP (group 2, Miami). Outcome measures were daily insulin requirement (DIR), HbA1...